Thrombopoietin therapy increases platelet yields in healthy platelet donors

Blood

Volumn 98, Issue 5, 2001, Pages 1339-1345

  Kuter, David J ^a,b,c,d   Goodnough, Lawrence T ^a,b,c,d   Romo, John ^a,b,c,d   DiPersio, John ^a,b,c,d   Peterson, Randolph ^a,b,c,d   Tomita, Dianne ^a,b,c,d   Sheridan, William ^a,b,c,d   McCullough, Jeffrey ^a,b,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; THROMBOPOIETIN;

ADULT; APHERESIS; ARTICLE; BLOOD DONOR; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; ECCHYMOSIS; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PARESTHESIA; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS;

EID: 0035469813     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.5.1339     Document Type: Article

References (29)

1. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337:1861-1869.
2. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine: first of two parts-blood transfusion. N Engl J Med. 1999;340:438-447.
3. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine: second of two parts-blood conservation. N Engl J Med. 1999;340:525-533.
4. Kuter DJ, Cebon J, Harker LA, Petz LD, McCullough J. Platelet growth factors: potential impact on transfusion medicine. Transfusion. 1999;39:321-332.
5. Menitove J. Standards for Blood Banks and Transfusion Services. 19th ed. Baltimore, MD: AABB Press; 1999.
6. Wallace EL, Churchill WH, Surgenor DM, Cho GS, McGurk S. Collection and transfusion of blood and blood components in the United States, 1994. Transfusion. 1998;38:625-636.
7. Lasky LC, Lin A, Kahn RA, McCullough J, Donor platelet response and product quality assurance in plateletpheresis. Transfusion. 1981;21:247-260.
8. Goodnough LT, Ali S, Despotis G, Dynis M, DiPersio JF. Economic impact of donor platelet count and platelet yield in apheresis products: relevance for emerging issues in platelet transfusion therapy. Vox Sang. 1999;76:43-49.
9. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77:1117-1124.
10. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med. 1997;336:404-409.
11. Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997;89:3118-3128.
12. Basser RL, Rasko JE, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet. 1996;348:1279-1281.
13. O'Malley CJ, Rasko JE, Basser RL, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood. 1996;88:3288-3298.
14. Goodnough LT, Kuter DJ, McCullough J, et al. Prophylactic platelet transfusions from healthy apheresis donors undergoing treatment with thrombopoietin. Blood. 2001;98:1346-1351.
15. Bussel J, Aledort L, Hayward C, et al. A prospective cross-sectional study to characterize selected autoimmune (Al) markers and report the incidence of antithrombopoietin antibodies in patients with immune thrombocytopenic purpura. Blood. 2000;96:250a.
16. Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood. 1996;88:511-521.
17. Bithell TC. Thrombocytosis. In: Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, eds. Clinical Hematology. 9th ed. Philadelphia, PA: Lea and Febiger; 1993:1390-1396.
18. Zingsem J, Zimmerman R, Wiesbach V, Glaser A, van Waeg G, Eckstein R. Comparison of COBE white cell reduction and standard plateletpheresis protocols in the same donors. Transfusion. 1997;37:1045-1049.
19. COB E Spectra Apheresis System Operators Manual for Use with Versions 4.7 and 5.1 Software Programs. Lakewood, CO: Cobe BCT; 1997.
20. Chambers LA, Kruskall MS, Pacini DG, Donovan LM. Febrile reactions after platelet transfusion: the effect of single versus multiple donors. Transfusion. 1990;30:219-221.
21. Gmur J, von Felten A, Osterwalder B. Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemia. Blood. 1983;62:473-479.
22. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000;132:364-368.
23. Schiffer CA, Lee EJ, Ness PM, Reilly J. Clinical evaluation of platelet concentrates stored for one to five days. Blood. 1986;67:1591-1594.
24. Stroncek DF, Clay ME, Petzoldt ML, et al. Treatment of normal individuals with granulocytecolony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion. 1996;36:601-610.
25. Patterson KL, Masuda SY, Brown SL. Safety profile of filgrastim (r-metHuG-CSF). In: Morystyn G, Dexter TM, Foote M, eds. Filgrastim (r-metHuGCSF) in Clinical Practice. 2nd ed. New York, NY: Marcel Dekker; 1998:583-601.
26. Li J, Xia Y, Bertino A, Cobum J, Kuter DJ. Characterization of an anti-thrombopoietin antibody that developed in a cancer patient following the injection of PEG-rHuMGDF. Blood. 1999;94:51a.
27. Yang C, Xia Y, Li J, Kuter DJ. The appearance of anti-thrombopoietin antibody and circulating thrombopoietin-IgG complexes in a patient developing thrombocytopenia after the injection of PEG-rHuMGDF. Blood. 1999;94:681a.
28. Cwida SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science. 1997;276:1696-1699.
29. Erickson-Miller CL, Delorme E, Tian SS, et al. Discovery and characterization of a selective, non-peptidyl thrombopoietin receptor agonist. Blood. 2000;96:675a.